Igkv1-117 Inhibitors
Chemical inhibitors of Igkv1-117 can disrupt its function through various biochemical interactions and pathways. Acrylamide, for example, can covalently modify the cysteine side chains in Igkv1-117, which might interfere with the protein's proper folding and functionality. This modification could alter the structural integrity of Igkv1-117, leading to a loss of function. Similarly, Chloroquine disrupts protein degradation by increasing the pH in lysosomes, which can impair the maturation process of Igkv1-117, affecting its functional availability. Bortezomib, MG-132, and Epoxomicin, all proteasome inhibitors, can lead to the accumulation of proteins that are typically marked for degradation. This accumulation can negatively impact the cellular environment, potentially inhibiting the function of Igkv1-117 by interfering with its degradation process. Lactacystin also targets the proteasome and may inhibit the function of Igkv1-117 by preventing the degradation of regulatory proteins that are crucial for its activity.
Monensin and Tunicamycin interfere with post-translational modification processes that are vital for the proper functioning of Igkv1-117. Monensin disrupts Golgi function, which is essential for the modification and trafficking of Igkv1-117, thereby inhibiting its function. Tunicamycin blocks N-linked glycosylation, a modification that can be crucial for the stability and folding of Igkv1-117, resulting in its functional inhibition. Auranofin inhibits thioredoxin reductase, an enzyme important for maintaining the redox balance within cells. The inhibition of this enzyme can lead to oxidative stress and improper protein folding, which can affect proteins like Igkv1-117. Lastly, Emetine and Cycloheximide target the protein synthesis machinery. Emetine blocks the elongation phase of protein synthesis on ribosomes, while Cycloheximide interferes with the translocation step in protein elongation, both of which can lead to a reduction in the synthesis of Igkv1-117, thereby inhibiting its function in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Acrylamide Solution, 40% | 79-06-1 | sc-3721 | 1 L | $98.00 | ||
Acrylamide can inhibit the protein Igkv1-117 by covalently modifying the nucleophilic side chains of cysteine residues, which may interfere with protein folding or function. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate inhibits dihydrofolate reductase, which is necessary for the synthesis of thymidylate and purine nucleotides. This inhibition can result in reduced proliferation of B-cells, thereby decreasing the production of Igkv1-117 as a consequence. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine raises intracellular pH by accumulating in lysosomes, which can disrupt protein degradation. This can lead to a decrease in the functional availability of Igkv1-117 by preventing its proper processing and maturation within the cell. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to the accumulation of misfolded proteins and potentially inhibiting the function of Igkv1-117 by disrupting its normal degradation pathway. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with the translocation step in protein elongation, which can indirectly lead to a functional reduction of Igkv1-117 by preventing its synthesis. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 inhibits the proteasome, similarly to Bortezomib, which can lead to an accumulation of misfolded or unfolded proteins and may inhibit the function of Igkv1-117 by disrupting its degradation. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor, which prevents the degradation of proteins, potentially leading to a reduction in functional Igkv1-117 protein by preventing its recycling or turnover. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin inhibits the proteasome, thereby potentially reducing the functional levels of Igkv1-117 by disrupting the degradation of regulatory proteins that control its activity. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $150.00 $210.00 $1899.00 | 39 | |
Auranofin inhibits thioredoxin reductase, which is involved in maintaining the redox balance in cells. Disruption of redox balance can affect the proper folding and function of proteins like Igkv1-117. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin disrupts Golgi function, which can inhibit the post-translational modification and proper trafficking of Igkv1-117, leading to its functional inhibition. | ||||||